The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration on Nov. 17, a day before a pivotal Senate Health, Education, Labor and Pensions Committee vote, after failing to secure sufficient congressional support. Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, was nominated by US President Donald Trump in August to replace former FDA Commissioner Marty Makary, who resigned in May. Her nomination faced resistance from Senate Republicans, including outgoing Chairman Bill Cassidy, Susan Collins and Roger Marshall, all of whom lost reelection bids, as well as criticism from Democrats and medical groups over childhood vaccination policy, mifepristone and vaping. The White House is weighing Marshall, a former obstetrician who recently lost his reelection bid, as a replacement. The FDA is conducting a safety review of mifepristone that it said will conclude by March 2027, while FDA Deputy Commissioner for Food Kyle Diamantas is serving as acting commissioner.